Sang-hoon YOON

Sang-hoon YOON

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in Complementary Therapies in Clinical Practice
Verified
Journal Article
Closed access
Chan-Young KwonChan-Young Kwon
Chan-Young Kwon
SYSang-hoon YOON
Sang-hoon YOON
BLBoram Lee
Boram Lee

17 October 2018 in Chinese Journal of Integrative Medicine
Verified
Journal Article
Closed access
PDF file
SYSang-hoon YOON
Sang-hoon YOON
YKYoon-Sik Kim
Yoon-Sik Kim
HJHee-Guen Jo
Hee-Guen Jo
Chan-Young KwonChan-Young Kwon
Chan-Young Kwon

1 June 2020 in Integrative Medicine Research
Verified
Journal Article
Open access
ELEunji Lee
Eunji Lee
SYSang-hoon YOON
Sang-hoon YOON
HKHyunho Kim
Hyunho Kim
YKYoung Doo Kim
Young Doo Kim
JLJungtae Leem
Jungtae Leem
Jinbong ParkJinbong Park
Jinbong Park
Ephedrae Herba is widely used to treat obesity. There is a concern for adverse events (AEs) using it and we need to develop strategies to attenuate it without its effectiveness for weight-reducing potential. We investigated the effects of a combination of Ephedra Herba with Zhizichi decoction and Phellodendri Cortex (Anmyungambi (AMGB) decoction) in reducing the incidence of Ephedra Herba-related AEs. We performed a retrospective chart review from a clinical case series of patients visiting the Jaonmi Korean Medicine Clinic (Seoul, Korea). The inclusion criteria was patients who were prescribed AMGB decoction, (containing Ephedrae Herba, Phellodendri Cortex, and Zhizichi decoction [Gardeniae Fructus, and Glycine Semen Preparata] in different proportions) for weight reduction. Exclusion of Phellodendri Cortex in the original AMGB preparation was allowed; conventional medications, acupuncture, and dietary supplements were not allowed. The primary outcome was absolute weight loss at the end of treatment. Twenty-seven patients (6 men and 21 women), aged 18-75 years (mean age, 42.6 ± 11.1 years) and the average treatment duration was 39.4 days. Absolute weight loss at the end of treatment was 4.49 ± 2.40 kg. Fifteen patients lost more than 5% weight (55.6%). Treatment >45 days resulted in significantly greater weight loss compared to treatment <30 days (p < 0.001). Not severe AEs were reported in 16 patients including constipation, fatigue, etc. A combination of Ephedra Herba with Zhizichi decoction and Phellodendri Cortex may be a safe and effective treatment for weight reduction in obese and overweight patients.

1 December 2020 in Integrative Medicine Research
Verified
Journal Article
Open access
JLJungtae Leem
Jungtae Leem
MCMoon Joo Cheong
Moon Joo Cheong
SYSang-hoon YOON
Sang-hoon YOON
HKHyunho Kim
Hyunho Kim
Hee-Geun JoHee-Geun Jo
Hee-Geun Jo
HKHyung Won Kang
Hyung Won Kang
Post-traumatic stress disorder (PTSD) has become an important public health problem. However, the conventional therapeutic strategy, including pharmacotherapy and cognitive behavioral therapy, has limitations. Neurofeedback is a technique that utilizes electroencephalography (EEG) signaling to monitor human physiological functions and is widely used to treat patients with PTSD. The purpose of our study is to assess the efficacy and safety level of neurofeedback treatment in patients with PTSD using quantitative EEG. This is a randomized, waitlist-controlled, assessor-blinded, clinical trial. Forty-six patients with PTSD will be randomly assigned at a 1:1 ratio into two groups. The participants in the treatment group will receive neurofeedback treatment for 50 min, twice a week, for 8 weeks (16 sessions). Quantitative EEG will be utilized to monitor the physiological functions and brain waves of the participants. A four-week follow-up period is planned. The participants in the control group will wait for 12 weeks. The primary outcome is the Korean version of PTSD Checklist-5 (PCL-5-K) score. The PCL-5-K scores on week 8 will be compared between the two groups. Anxiety, depression, insomnia, emotions, EEG, quality-of-life, and safety level will be assessed as secondary outcomes. This trial will describe a clinical research methodology for neurofeedback in patients with PTSD. The numerous subjective and objective secondary outcomes add to the value of this trial’s results. It will also suggest a therapeutic strategy for utilizing quantitative EEG in patients with PTSD. Our trial will provide basic evidence for the management of PTSD via an integrative treatment. Clinical Research Information Service (CRIS): KCT0003271.

1 April 2019 in European Journal of Integrative Medicine
Verified
Journal Article
Closed access
SYSang-hoon YOON
Sang-hoon YOON
Chan-Young KwonChan-Young Kwon
Chan-Young Kwon
JLJungtae Leem
Jungtae Leem

20 August 2017 in The Acupuncture
Verified
Journal Article
Open access
SYSang-hoon YOON
Sang-hoon YOON
YKYoon Sik Kim
Yoon Sik Kim
MKMin Goo Kwon
Min Goo Kwon
Chan-Young KwonChan-Young Kwon
Chan-Young Kwon